Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  IGF ligand neutralizing antibody BI 836845
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-5 of 5 for your search:
Start Over
Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1280.2, 2010-021714-29, NCT01317420
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1280.4, 2013-001110-15, NCT02123823
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours
Phase: Phase I
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1280.15, NCT02145741
BI 836845 Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1280.16, NCT02191891
BI 836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1280.8, 2013-004011-41, NCT02204072
Start Over